cmAngio®
Overview
cmAngio® by CureMetrix is an artificial intelligence software designed to detect and localize breast arterial calcifications (BAC) on routine screening mammograms. The tool serves as an adjunct for radiologists, enabling them to identify these incidental vascular findings during standard breast cancer screenings without requiring additional imaging, patient procedures, or radiation exposure.
The software is primarily utilized by radiologists within breast imaging centers, hospitals, and outpatient clinics. By identifying BAC—which are linked to systemic vascular conditions—the tool assists clinicians in flagging patients who may benefit from further cardiovascular evaluation by primary care providers or cardiologists.
Workflow Integration and Capabilities:
- Multi-Platform Compatibility: Integrates with major mammography platforms, including validated compatibility with Hologic and GE HealthCare imaging systems.
- Image Modalities: Analyzes both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) screening images.
- Visual Reporting: Generates a dedicated scorecard and highlights BAC directly on image thumbnails with visual contours to facilitate rapid review.
- PACS Integration: Connects directly into existing Picture Archiving and Communication Systems (PACS) and standard mammography workflows.
- Adjustable Settings: Features an adjustable operating point, allowing clinical sites to align the software’s sensitivity and specificity with their specific practice protocols.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-based detection of Breast Arterial Calcifications (BAC)
- Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams
- Provides visualization of BAC location on a scorecard
- Enables BAC identification and reporting without additional radiation or procedures
- Compatible with any DICOM-compliant viewer
- Adjustable operating point to meet clinical goals
- Quick and easy installation (less than an hour)
- Cybersecure and HIPAA-compliant
- Demonstrated performance across all breast densities
- Generates a CureMetrix Bradley Scoreu2122 to measure coronary risk (in development/previously mentioned)
Use Cases
- Early identification of women at risk for cardiovascular disease through incidental BAC findings on mammograms
- Support for radiologists in assessing and reporting Breast Arterial Calcifications (BAC)
- Facilitating referrals for further cardiovascular evaluation with primary care providers or cardiologists
- Integrating cardiovascular health assessment into routine mammography screening without additional procedures
- Maximizing the clinical value of a single mammogram
- Improving patient outcomes by identifying under-recognized risks in women's health
What Physicians Need to Know
Leverage cmAngiou00ae to transform routine mammograms into a dual-purpose screening for both breast cancer and cardiovascular risk. Pay close attention to the AI-generated BAC findings and associated scores, especially in younger women, as these can be early indicators of significant cardiovascular risk. Consider these findings when discussing patient risk profiles and recommending further cardiovascular evaluation or preventative strategies with primary care physicians or cardiologists. Tracking the Bradley Scoreu2122 over time can help monitor changes in a patient's cardiovascular risk profile.
cmAngiou00ae is designed for quick and easy installation and is compatible with any DICOM-compliant viewer. It processes both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) exams. The software has received FDA clearance for use with Hologic and GE Healthcare mammography imaging platforms, expanding its commercial footprint and integration into diverse clinical environments.
Details
| Category | Cardiology AI, OB/GYN AI, Radiology & Imaging AI |
| Pricing | Contact for details — Not publicly available. Limited-time offers for no-cost implementation and service may be available. |
| Deployment | Cloud-based (inferred from similar CureMetrix products) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated cmAngio® is an FDA-cleared Artificial Intelligence (AI) based detection software (K250754) to identify Breast Arterial Calcifications (BAC) in FFDM and DBT screening mammograms. It received clearance on April 10, 2025, and expanded clearance to include GE Healthcare platforms on April 15, 2025. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology |
What the Web Says
cmAngiou00ae by CureMetrix is an FDA-cleared AI software designed to detect and localize breast arterial calcifications (BAC) on standard screening mammograms (both full-field digital mammography and digital breast tomosynthesis). This technology aims to transform mammograms into a dual screening for both breast cancer and potential cardiovascular disease risk, as BAC has been linked to an elevated risk for heart disease and stroke. The software boasts high accuracy with an AUC of 0.98 across FFDM and DBT.
Overall: PositiveStrengths
- Detects breast arterial calcifications (BAC) on standard mammograms without additional radiation or procedures.
- Provides a dual screening for breast cancer and cardiovascular disease risk in one visit.
- High accuracy with an AUC of 0.98 across FFDM and DBT.
- Can identify BAC in cases missed by human readers.
- PACS agnostic and cloud-based, making it easy to implement.
- HIPAA and DICOM compliant, ensuring data security and regulatory compliance.
Limitations
- There are currently no established national guidelines for identifying, evaluating, and reporting BAC, leading to inconsistent practices.
- The AI device does not currently provide categorization of BAC severity.
- Pricing is not publicly transparent and requires direct contact with the vendor.
- No specific reviews from Reddit, G2, or Capterra were found for cmAngiou00ae itself, only general platform reviews.
Based on reviews from: CureMetrix, PubMed Central, AuntMinnie, Oxford Academic, Physician Ai Tools, SoftwareSuggest, G2, Capterra, Indeed.com
Last updated: 2026-07-18
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate cmAngio®
Press & Coverage
No FAQs available yet for this tool.
Compare cmAngio®
VS
VS
VS
VS
Investors who backed cmAngio®
Funded through the company that built this tool.
